default author photo

Guruprasad Medigeshi

Government of India - Translational Health Science & Technology Institute (THSTI)

SCHOLARLY PAPERS

4

DOWNLOADS

1,189

TOTAL CITATIONS

6

Scholarly Papers (4)

Actions:
Email selected abstracts
1.

Cellular Immune Responses are Preserved and May Contribute to Chadox1 ChAdOx1 nCoV-19 Vaccine Effectiveness Against Infection Due to SARS-CoV-2 B·1·617·2 Delta Variant Despite Reduced Virus Neutralisation

Number of pages: 42 Posted: 16 Jul 2021
Ramachandran Thiruvengadam, Amit Awasthi, Guruprasad Medigeshi, Sankar Bhattacharya, Shailendra Mani, Sridhar Sivasubbu, Tripti Srivatsava, Sweety Samal, Deepika Rathna Murugesan, Bapu Koundinya Desiraju, Pallavi Kshetrapal, Rajesh Pandey, Vinod Scaria, Praveen Kumar Malik, Juhi Taneja, Akshay Binayke, Tarini Vohra, Aymaan Zaheer, Deepak Rathore, Naseem Ahmed Khan, Heena Shaman, Shubbir Ahmed, Rajesh Kumar, Suprit Deshpande, Chandru Subramani, Nitya Wadhwa, Nimesh Gupta, Anil K. Pandey, Jayanta Bhattacharya, Anurag Agrawal, Sudhanshu Vrati, Shinjini Bhatnagar, Pramod Kumar Garg and DBT Consortium for COVID-19 Research
Translational Health Science and Technology Institute, Government of India - Immuno-biology Lab, Government of India - Translational Health Science & Technology Institute (THSTI), Translational Health Science and Technology Institute, Government of India - Infection and Immunology Center, CSIR-Institute of Genomics and Integrative Biology, Translational Health Science and Technology Institute, Government of India - Infection and Immunology Center, Translational Health Science and Technology Institute, Translational Health Science and Technology Institute, Translational Health Science and Technology Institute, CSIR-Institute of Genomics and Integrative Biology, CSIR-Institute of Genomics and Integrative Biology, ESIC Medical College and Hospital, ESIC Medical College and Hospital, Translational Health Science and Technology Institute, Translational Health Science and Technology Institute, Translational Health Science and Technology Institute, Translational Health Science and Technology Institute, Translational Health Science and Technology Institute, Government of India - Vaccine and Infectious Disease Research Center, Translational Health Science and Technology Institute, Translational Health Science and Technology Institute, Translational Health Science and Technology Institute, Regional Center for Biotechnology, Translational Health Science and Technology Institute, National Institute of Immunology, ESIC Medical College and Hospital, Translational Health Science and Technology Institute, CSIR-Institute of Genomics and Integrative Biology, Regional Center for Biotechnology, Translational Health Science and Technology Institute, Translational Health Science and Technology Institute and Independent
Downloads 826 (73,650)
Citation 6

Abstract:

Loading...

2.

Selection of Optimum Formulation of RBD-Based Protein Sub-Unit Covid19 Vaccine (Corbevax) Based on Safety and Immunogenicity in an Open-Label, Randomized Phase-1 and 2 Clinical Studies

Downloads 169 (444,808)

Selection of Optimum Formulation of RBD-Based Protein Sub-Unit Covid19 Vaccine (Corbevax) Based on Safety and Immunogenicity in an Open-Label, Randomized Phase-1 and 2 Clinical Studies

Number of pages: 48 Posted: 09 Mar 2022
Subhash Thuluva, Vikram Paradkar, Kishore Thuraga, Subbareddy Gunneri, Vijay Yerroju, Rammohanreddy Mogulla, Mahesh Kyasani, Senthilkumar Manoharan, Guruprasad Medigeshi, Janmejay Singh, Heena Shaman, Chandramani Singh and Venkateshwar Rao A
Biological E Limited, Biological E Limited, Biological E Limited, Biological E Limited, Biological E Limited, Biological E Limited, Biological E Limited, Biological E Limited, Government of India - Translational Health Science & Technology Institute (THSTI), Government of India - Vaccine and Infectious Disease Research Center, Government of India - Vaccine and Infectious Disease Research Center, All India Institute of Medical Sciences (AIIMS), Bhopal and St. Theresa s Hospital - Department of General Medicine
Downloads 93 (732,131)

Abstract:

Loading...

COVID-19, Vaccine, Receptor Binding Domain, SARS-CoV-2, Spike protein, Protein subunit

Selection of Optimum Formulation of RBD-Based Protein Sub-Unit COVID19 Vaccine (Corbevax) Based on Safety and Immunogenicity in an Open-Label, Randomized Phase-1 and 2 Clinical Studies

Number of pages: 50 Posted: 11 Mar 2022
Subhash Thuluva, Vikram Paradkar, Kishore Thuraga, Subbareddy Gunneri, Vijay Yerroju, Rammohanreddy Mogulla, Mahesh Kyasani, Senthilkumar Manoharan, Guruprasad Medigeshi, Janmejay Singh, Heena Shaman, CM Singh and Venkateshwar Rao A
Biological E Limited, Biological E Limited, Biological E Limited, Biological E Limited, Biological E Limited, Biological E Limited, Biological E Limited, Biological E Limited, Government of India - Translational Health Science & Technology Institute (THSTI), Government of India - Vaccine and Infectious Disease Research Center, Government of India - Vaccine and Infectious Disease Research Center, All India Institute of Medical Sciences (AIIMS) - Department of Community and Family Medicine and St. Theresa s Hospital - Department of General Medicine
Downloads 76 (840,816)

Abstract:

Loading...

COVID-19, Vaccine, Receptor binding domain, SARS-CoV-2, Spike protein, Protein subunit

3.

Standardization and Harmonization of SARS-COV-2 Assays Offered by the CEPI Centralized Laboratory Network in Support for Vaccine Clinical Trials

Number of pages: 23 Posted: 21 Jun 2023
Mark Maximilian Manak, Luc Gagnon, Steven Phay-Tran, Philipa Levesque-Damphousse, Aymeric Fabie, Matthieu Daugan, Sarwat Tahsin Khan, Pamela Proud, Bethan Hussey, Daniel Knott, Guruprasad Medigeshi, Neha Garg, Anbalagan Anantharaj, Rubhana Raqib, Protim Sarker, Mohammad Mamun Alam, Mustafizur Rahman, Marta Murreddu, Angela Balgobind, Rick Hofman, Silvia Grappi, Emanuele Montomoli, Rosa Coluccio, Pierpaolo Calandro, Giada Mattiuzzo, Sandra Prior, Yann Le Duff, Mark Page, Jane Mitchell, Lauren M. Schwartz, Yannic C. Bartsch, Ali Azizi, Valentina Bernasconi and CLN Network
Coalition for Epidemic Preparedness Innovations, Nexelis/Q2 Solutions, Nexelis/Q2 Solutions, Nexelis/Q2 Solutions, Nexelis/Q2 Solutions, Nexelis/Q2 Solutions, Nexelis/Q2 Solutions, UK Health Security Agency, UK Health Security Agency, UK Health Security Agency, Government of India - Translational Health Science & Technology Institute (THSTI), Government of India - Translational Health Science & Technology Institute (THSTI), Government of India - Translational Health Science & Technology Institute (THSTI), International Centre for Diarrheal Disease Research (icddr,b), International Centre for Diarrheal Disease Research (icddr,b), International Centre for Diarrheal Disease Research (icddr,b), International Centre for Diarrheal Disease Research (icddr,b), Viroclinics Biosciences, Viroclinics Biosciences, VisMederi SRL, VisMederi SRL, VisMederi SRL, VisMederi SRL, VisMederi SRL, Government of the United Kingdom - Vaccines (Research and Development), affiliation not provided to SSRN, Government of the United Kingdom - The Medicines and Healthcare Products Regulatory Agency, Government of the United Kingdom - The Medicines and Healthcare Products Regulatory Agency, Government of the United Kingdom - The Medicines and Healthcare Products Regulatory Agency, Gorman Consulting, Gorman Consulting, Coalition for Epidemic Preparedness Innovations, Coalition for Epidemic Preparedness Innovations and Independent
Downloads 124 (580,653)

Abstract:

Loading...

SARS-CoV-2, Vaccine, standardization, global, ELISA, Neutralization assays, ELISpot assays, protection from disease

4.

Antibody Response to SARS-CoV2 Among COVID-19 Confirmed Cases, and Correlates with Neutralizing Assay in a Subgroup of Patients in Delhi National Capital Region, India

Number of pages: 16 Posted: 16 May 2022
Dr. Puneet Misra, Shashi Kant, Randeep Guleria, Sanjay K. Rai, Abhishek Jaiswal, Suprakash Mandal, Guruprasad Medigeshi, Mohammad Ahmad, Anisur Rahman, Meenu Sangral, Kapil Yadav, Mohan Bairwa, Partha Haldar and Parveen Kumar
Department of Computer Science, All India Institute of Medical Sciences (AIIMS) - Department of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS), Bhopal, All India Institute of Medical Sciences (AIIMS) - Department of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS) - Department of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi - Centre for Community Medicine, Government of India - Translational Health Science & Technology Institute (THSTI), World Health Organization (WHO) - World Health Organization (WHO) Country Office for Yemen, World Health Organization (WHO) - World Health Organization (WHO) Country Office for Yemen, All India Institute of Medical Sciences (AIIMS) - Department of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS) - Department of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS) - Department of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS) - Department of Community and Family Medicine and Government of India - Translational Health Science & Technology Institute (THSTI)
Downloads 70 (875,328)

Abstract:

Loading...

Infectious disease, COVID-19, Antibody response